Related Experiment Video
Updated: Feb 26, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.3K
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Simran Sindhu1,2, Lana H Gimber3, Lee Cranmer4
1Department of Medicine, Division of Hematology/Oncology, The University of Arizona, 1501 N Campbell Ave, Tucson, AZ, 85724, USA.
Journal for Immunotherapy of Cancer
|July 19, 2017
Summary
This study shows that angiosarcoma can express PD-L1, a target for immunotherapy. A patient with advanced angiosarcoma responded well to PD-1 therapy, indicating a potential new treatment for this rare cancer.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Angiosarcomas are aggressive cancers of malignant endothelial cells with poor prognoses.
- Current treatments for metastatic angiosarcoma offer limited efficacy.
- Immunotherapy targeting PD-1/PD-L1 has shown promise in various cancers but its role in angiosarcoma is unreported.
